Ocean Biomedical Stock Forecast

Stock Price Forecast

There is currently no analyst price target forecast available for Ocean Biomedical.

Analyst Consensus: n/a

Target	Low	Average	Median	High
Price	n/a	n/a	n/a	n/a
Change	n/a	n/a	n/a	n/a

Analyst Ratings

There are currently no analyst ratings available for OCEA.

Recommendation Trends

Rating	Apr '23	May '23
Strong Buy	2	0
Buy	0	0
Hold	0	0
Sell	0	0
Strong Sell	0	0
Total	2	0

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Howard Halpern Taglich Brothers	Taglich Brothers	Buy Initiates $20	Buy	Initiates	$20	+2,757.14%	May 31, 2023
Tony Butler EF Hutton	EF Hutton	Strong Buy Initiates $17	Strong Buy	Initiates	$17	+2,328.57%	May 25, 2023
Michael King EF Hutton	EF Hutton	Strong Buy Maintains $10 → $17	Strong Buy	Maintains	$10 → $17	+2,328.57%	Apr 27, 2023
Michael King EF Hutton	EF Hutton	Strong Buy Reiterates $10	Strong Buy	Reiterates	$10	+1,328.57%	Apr 13, 2023
Sid Rajeev Fundamental Research Corp.	Fundamental Research Corp.	Strong Buy Initiates $16	Strong Buy	Initiates	$16	+2,242.86%	Mar 16, 2023

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

-3.14

from -0.99

EPS Next Year

-0.91

from -3.14

Fiscal Year	FY 2019	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024
Period Ending	Dec 31, 2019	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024
Revenue	-	-	-	-	-	-
Revenue Growth	-	-	-	-	-	-
EPS	-0.01	-0.09	-3.57	-0.99	-3.14	-0.91
EPS Growth	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-
No. Analysts	-	-	-	-	3	3

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2023	2024
High	n/a	n/a
Avg	n/a	n/a
Low	n/a	n/a

Revenue Growth

Revenue Growth	2023	2024
High	-	-
Avg	-	-
Low	-	-

EPS Forecast

EPS	2023	2024
High	-3.23	-0.93
Avg	-3.14	-0.91
Low	-3.02	-0.87

EPS Growth

EPS Growth	2023	2024
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.